alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### Kilgo *v.*Continental Casualty Company.

Dissenting opinion delivered February 2, 1920.

For majority opinion, see 140 Ark 336.

McCulloch, C. J.,

(dissenting). It must be and is conceded that under the principles of law heretofore announced by this court appellant was not required, as a condition to the maintenance of this action to refund the money paid for the release. *St. L., I. M. & S. Ry. Co.*v. *Smith,*82 Ark. 105.

The requirement that money paid for a release must be refunded and the requirment that suit to rescind be brought within a reasonable time go hand in hand, and where one is applicable the other is likewise, and for the same reason, applicable. The reason, as I understand it, is that where the contract of settlement and release is merely voidable on account of fraud the dissatisfied party must make his election within a reasonable time after discovery of the fraud, either to abide by the contract or to repudiate it and return the consideration received, The return, or offer to return, of the consideration constitutes the overt act of rescission and the suit to compel rescission can be begun at any time during the statutory period of limitations. It therefore seems clear to me that in all cases where the *638circumstances are such that the consideration need not be returned as a prerequisite■ to a suit on,the original cause of action, such suit may be instituted at any time within the statutory period of limitation and not necessarily within what may be found to be a reasonable time. This is so because the release contract is void, not mereely voidable, and it does not change the time allowed by law for bringing suit. Neither formal repudiation of the release nor cancellation of it by judgment or decree of court is, under such circumstances, essential to the maintenance of suit on the original cause of action, which proceeds in disregard of the void release, the amount paid being tre.ated as a credit on the sum due. I fail to comprehend the logic of this court’s position in holding that, while repudiation or rescission of the release contract is not essential, action on the original claim must commence within a reasonable time.
**Exhibit32.1**

**CERTIFICATIONPURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Each of the undersignedofficers of Enterprise Informatics Inc. (the “Company”) hereby certifies to hisknowledge that the Company’s quarterly report on Form 10-Q for the period endedMarch 31, 2007 (the “Report”), as filed with the Securities and ExchangeCommission on the date hereof, fully complies with the requirements ofSection 13(a) or 15(d), as applicable, of the Securities Exchange Act of1934, as amended, and that the information contained in the Report fairlypresents, in all material respects, the financial condition and results ofoperations of the Company.  This certification is provided solely pursuantto 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, and shall not be deemed to be a part of the Reportor “filed” for any purpose whatsoever.
| Dated:  May 15, 2007 |   |
|---------------------------|--------|
|                      |   |
| /s/ Alan Kiraly           |   |
|                      |   |
| Alan Kiraly               |   |
| Chief Executive Officer   |   |

 
| Dated:  May 15, 2007 |   |
|---------------------------|--------|
|                      |   |
| /s/ John W. Low           |   |
|                      |   |
| John W. Low               |   |
| Chief Financial Officer   |   |

 

A signed original of thiswritten statement required by Section 906 has been provided to EnterpriseInformatics Inc. and will be retained by Enterprise Informatics Inc. andfurnished to the Securities and Exchange Commission or its staff upon request.

1

----
§ 520.1284 Liothyronine. ( a ) *Specifications.* Each tablet contains 60 or 120 micrograms (μg) liothyronine as the sodium salt.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer orally to dogs at levels up to 12.8 μg per kilogram (/kg) of body weight per day. Dosage should be adjusted according to the severity of the condition and the response of the patient. Dosage at the total replacement level (12.8 μg/kg of body weight) should be considered for initiating therapy and then titrated downward for optimum maintenance effect. Twice daily administration is recommended.
( 2 ) *Indications for use.* For treatment of hypothyroidism in dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[78 FR 28823, May 20, 2014]
---

---



Exhibit 14.1

# CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM

We consent to the incorporation by
reference in the Registration Statements Form S-8 (File Nos. 333-102288 and 333-92491) and
Form F-3 (File Nos. 333-115826, 333-114428, 333-47842 and 333-92493) of our report dated
June 6, 2005 (except as to Note 1b, 10 and 11e which are dated July 10, 2005 and except as to Notes 1g, 2v, 7b,
16d, 16h and 18 which are dated January 31, 2006), with respect to the consolidated
financial statements of Nur Macroprinters Ltd. included in this Annual Report on Form 20-F/A
Amendment No. 1 for the year ended December 31, 2004.

|Tel-Aviv, IsraelMarch 9, 2006 |  | /s/ KOST FORER GABBAY & KASIERERKOST FORER GABBAY & KASIERERA Member of Ernst & Young Global
|----------------------------- |  | --------------------------------------------------------------------------------------------



---

---
----

|   | (1) | In connection with the Annual Report of the Company on form 10-K for the twelve month period ended May 31, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) and Section 15(d) of the Securities and Exchange Act of 1934; and |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company for the periods presented therein. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | By:                            | /ss/Gary J. Allen    |   |
|--------|--------------------------------|-------------------------------------|--------|
|   |                           | Gary J. Allen                       |   |
|   |                           | Senior Corporate Controller         |   |
|   |                           | Principal Accounting Officer        |   |
|   |                           |                                |   |
|   | Date: September 13, 2011  |

----
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM WESTERN
WIRELESS CONSOLIDATED BALANCE SHEET AND STATEMENT OF OPERATIONS AS OF AND FOR
THE QUARTER ENDED MARCH 31, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH 10-Q.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                          35,845
<SECURITIES>                                         0
<RECEIVABLES>                                   32,191
<ALLOWANCES>                                     4,507
<INVENTORY>                                     23,723
<CURRENT-ASSETS>                               120,084
<PP&E>                                         768,197
<DEPRECIATION>                                 130,560
<TOTAL-ASSETS>                               1,325,709
<CURRENT-LIABILITIES>                          152,831
<BONDS>                                        873,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       570,972
<OTHER-SE>                                   (271,094)
<TOTAL-LIABILITY-AND-EQUITY>                 1,325,709
<SALES>                                          6,904
<TOTAL-REVENUES>                                71,560
<CGS>                                           13,065
<TOTAL-COSTS>                                  108,951
<OTHER-EXPENSES>                                17,782
<LOSS-PROVISION>                                 2,593
<INTEREST-EXPENSE>                              17,360
<INCOME-PRETAX>                               (55,173)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (55,173)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (55,173)
<EPS-PRIMARY>                                   (0.79)
<EPS-DILUTED>                                        0
        

</TABLE>
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7404 Reported in House (RH)]

<DOC>

                                                 Union Calendar No. 451
118th CONGRESS
  2d Session
                                H. R. 7404

                          [Report No. 118-543]

   To require annual reports on counter illicit cross-border tunnel 
                  operations, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 16, 2024

 Mr. Crane (for himself, Mr. Correa, Mr. Biggs, Mr. Duncan, Mr. Gosar, 
Mr. Guest, Mr. Higgins of Louisiana, Mr. Luttrell, Mr. McCaul, and Mr. 
    Ogles) introduced the following bill; which was referred to the 
                     Committee on Homeland Security

                              June 7, 2024

 Additional sponsors: Mr. D'Esposito, Mr. Burlison, Mr. Thanedar, Mr. 
                       Rosendale, and Mr. Pfluger

                              June 7, 2024

  Reported from the Committee on Homeland Security; committed to the 
 Committee of the Whole House on the State of the Union and ordered to 
                               be printed

_______________________________________________________________________

                                 A BILL

 
   To require annual reports on counter illicit cross-border tunnel 
                  operations, and for other purposes.

 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Subterranean Border Defense Act''.

SEC. 2. ANNUAL REPORTS ON COUNTER ILLICIT CROSS-BORDER TUNNEL 
              OPERATIONS.

    Paragraph (2) of section 7134(a) of the James M. Inhofe National 
Defense Authorization Act for Fiscal Year 2023 (Public Law 117-263; 6 
U.S.C. 257 note) is amended by inserting ``and annually thereafter'' 
after ``development of the strategic plan''.
                                                 Union Calendar No. 451

118th CONGRESS

  2d Session

                               H. R. 7404

                          [Report No. 118-543]

_______________________________________________________________________

                                 A BILL

   To require annual reports on counter illicit cross-border tunnel 
                  operations, and for other purposes.

_______________________________________________________________________

                              June 7, 2024

   Committed to the Committee of the Whole House on the State of the 
                    Union and ordered to be printed
```
§ 520.170 Bexagliflozin. ( a ) *Specifications.* Each tablet contains 15 milligrams bexagliflozin.
( b ) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer one tablet by mouth to cats 6.6 lb (3.0 kg) or greater once daily, at approximately the same time each day, with or without food, and regardless of blood glucose level.
( 2 ) *Indications for use.* To improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[88 FR 16547, Mar. 20, 2023]
EXHIBIT 23


                           INDEPENDENT ACCOUNTANTS' CONSENT


             The Board of Directors
             Statewide Financial Corp.:

             We consent to incorporation by reference in the Registration
             Statements (No. 33-96844) on Form S-8, (No. 33-09665) on
             Form S-8, (No. 333-46063) on Form S-8 and (No. 333-46065) on
             Form S-8 of our report dated January 26, 1998, relating to
             the consolidated statements of financial condition of
             Statewide Financial Corp. and subsidiary as of December 31,
             1997 and 1996 and the related consolidated statements of
             income, shareholders' equity, and cash flows for the years
             ended December 31, 1997 and 1996, and the nine-month period
             ended December 31, 1995 which report appears in the December
             31, 1997 Annual Report on Form 10-K of Statewide Financial
             Corp.


                                                KPMG Peat Marwick LLP



             Short Hills, New Jersey
             March 26, 1998
#### Malcolm v. Malcolm

*Stahlman & Carson,*for plaintiff.

*D. M. Anderson, Jr.,*for defendant.

April 19,1951.

Gibson, P. J.,

— The peculiar method of conducting this case requires some correction.

Plaintiff filed her complaint in divorce on September 3, 1948, praying for an absolute divorce on the one ground of indignities to the person.

On February 6, 1950, plaintiff filed a petition to amend the complaint by adding, as an additional ground for divorce, wilful and malicious desertion. On this petition, a rule was granted returnable to March 6, 1949. Since the date of the order was February 6, 1950, it is obvious that the year for the return day must have been 1950. Endorsed on this peti*458tion is the following: “And now February 20, 1950 a copy of the within petition for an amended complaint received and issuance of the rule waived. D. M. Anderson, Atty. for defendant.” No answer to the rule was filed and no further steps regarding an amendment were taken.

The master recommends a decree of divorce on the one ground of desertion, that being the ground alleged in the incomplete proceeding to amend. The master could not have recommended a decree on any other ground because plaintiff abandoned at the hearing before the master the charge of indignities and offered no testimony on that charge.

It is required in divorce proceedings that any decree of divorce entered must be for the very cause alleged in the complaint, and under this record as it now stands we cannot grant a decree on the ground of desertion for it is not a reason set forth in the complaint and the amendment of the complaint has not yet been allowed by the court.

Since after 20 days following the waiver of the rule on February 20, 1950, the rule could have been made absolute and leave to amend been secured, and for the purpose of avoiding circuity of action this can now be done as of the proper time, and since the proceeding for a divorce on the ground of desertion appears to be meritorious, we will now do what should have been done at that time, and as to the proceedings after that date, treat them as though they had followed the decree making the rule to amend absolute.

And now, April 19, 1951, it is ordered and decreed that the rule issued February 6, 1950, and returnable March 6, 1950, the issuance of which rule was waived by counsel for defendant on February 20, 1950, be made absolute in default of an answer as of March 14, 1950, and leave to amend the complaint is hereby granted.as of that date.
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7478 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7478

 To amend the Higher Education Act of 1965 to require institutions of 
  higher education, as a condition of participation in programs under 
 title IV of such Act, to include a prohibition of antisemitic conduct 
       in all documents relating to student or employee conduct.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 29, 2024

  Mr. Yakym introduced the following bill; which was referred to the 
                Committee on Education and the Workforce

_______________________________________________________________________

                                 A BILL

 
 To amend the Higher Education Act of 1965 to require institutions of 
  higher education, as a condition of participation in programs under 
 title IV of such Act, to include a prohibition of antisemitic conduct 
       in all documents relating to student or employee conduct.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Promote Restoring Order To End 
Campus Targeting of Jewish Students and Faculty Act'' or the ``PROTECT 
Jewish Student and Faculty Act''.

SEC. 2. PROHIBITION OF ANTISEMITIC CONDUCT.

    Section 487(a) of the Higher Education Act of 1965 (20 U.S.C. 
1094(a)) is amended by adding at the end the following:
            ``(30) The institution will include, in all documents and 
        other resources relating to student or employee conduct on 
        campus--
                    ``(A) the working definition of antisemitism of the 
                International Holocaust Remembrance Alliance; and
                    ``(B) a statement that antisemitic conduct is 
                prohibited on campus, and that such conduct--
                            ``(i) by a student may result in the 
                        expulsion of the student from the institution; 
                        and
                            ``(ii) by an employee may result in the 
                        termination of the employee's employment at the 
                        institution.''.
                                 <all>
```
§ 200.10 Contract facilities (including consulting laboratories) utilized as extramural facilities by pharmaceutical manufacturers. ( a ) Section 704(a) of the Federal Food, Drug, and Cosmetic Act specifically authorizes inspection of consulting laboratories as well as any factory, warehouse, or establishment in which prescription drugs are manufactured, processed, packed, or held.
( b ) The Food and Drug Administration is aware that many manufacturers of pharmaceutical products utilize extramural independent contract facilities, such as testing laboratories, contract packers or labelers, and custom grinders, and regards extramural facilities as an extension of the manufacturer's own facility.
( c ) The Food and Drug Administration reserves the right to disclose to the pharmaceutical manufacturer, or to the applicant of a new drug application (NDA) or to the sponsor of an Investigational New Drug (IND) Application, any information obtained during the inspection of an extramural facility having a specific bearing on the compliance of the manufacturer's, applicant's, or sponsor's product with the Federal Food, Drug, and Cosmetic Act. The Food and Drug Administration's position is that by the acceptance of such contract work, the extramural facility authorizes such disclosures.
( d ) The Food and Drug Administration does not consider results of validation studies of analytical and assay methods and control procedures to be trade secrets that may be withheld from the drug manufacturer by the contracted extramural facility.
[40 FR 13996, Mar. 27, 1975, as amended at 55 FR 11576, Mar. 29, 1990]
EXHIBIT 10.51

                              Note to Exhibit 10.51



         The following Trust Agreement is substantially identical in all
material respects to five additional Trust Agreements except as follows:

<TABLE>
<CAPTION>

Owner Participant                                       Date                                    Aircraft (Tail No.)
-----------------                                       ----
<S>                                                     <C>                                     <C>
NCC Charlie Company*                                    September 10, 1998*                     N575ML*
NCC Charlie Company                                     September 10, 1998                      N576ML
General Electric Capital Corporation                    November 10, 1998                       N577ML
General Electric Capital Corporation                    November 10, 1998                       N578ML
Castle Harbour Leasing Inc.                             December 10, 1998                       N579ML
NCC Charlie Company                                     January 25, 1999                        N580ML
</TABLE>




------------------

*   Filed document